FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 788 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 Study Reinforces Treatment Idea for Cancer with Microsatellite Instability October 2, 2020 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative... February 27, 2025 Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... May 18, 2021 Load more HOT NEWS FDA Proposes Changes to Mammography Standards to Inform Women About Breast... Cancer Rehabilitation Starts at Diagnosis: Part II Your NCI: Top Priorities from AACR 2026 Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene
